Latest stories on KPTI
Karyopharm: 'Hold' On Slow XPOVIO U.S. Sales But 2026 Milestones Still On Deck
Seeking Alpha42 · neutralanalyst
RBC Capital reiterates Karyopharm stock rating on compensation plan
Investing.com Analyst Ratings50 · neutralanalyst
Karyopharm Therapeutics: Balance Sheet Poor But Catalysts Ahead
Seeking Alpha56 · neutralproduct/pr
Karyopharm drops 21% following disclosure of executive cash retention plan
Seeking Alpha34 · bearishgeneral
Karyopharm Launches 2026 Executive Retention Incentive Program
TipRanks55 · neutralgeneral
Karyopharm Therapeutics Inc. (KPTI) files 8-K
SEC 8-K50 · neutralgeneral
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KPTI Stock News
StockTitan50 · neutralgeneral
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire50 · neutralgeneral
Karyopharm: Xpovio Revenue Stagnation And Toxicity Concerns Justify Sell
Seeking Alpha28 · bearishanalyst
Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026 | KPTI Stock News
StockTitan56 · neutralproduct/pr
Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026
PR Newswire56 · neutralproduct/pr
Karyopharm Therapeutics Inc. (KPTI) Discusses Phase III SENTRY Trial Results of Selinexor Plus Ruxolitinib in Myelofibrosis Transcript
Seeking Alpha59 · neutralproduct/pr
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | KPTI Stock News
StockTitan50 · neutralgeneral
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire50 · neutralgeneral
Karyopharm Expands Equity Incentives and Launches PSU Program
TipRanks48 · neutralgeneral
Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference
PR Newswire55 · neutralgeneral
Karyopharm (KPTI) Leans on SENTRY in Pivotal Call
TipRanks56 · neutralearnings
Karyopharm Therapeutics Q1 Earnings Call Highlights
Yahoo Top63 · neutralearnings
Karyopharm Therapeutics Inc. 2026 Q1 - Results - Earnings Call Presentation
Seeking Alpha50 · neutralearnings
Karyopharm Therapeutics GAAP EPS of -$1.24 beats by $0.25, revenue of $35.07M beats by $3.67M
Seeking Alpha63 · neutralearnings
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment
PR Newswire59 · neutralproduct/pr